Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Jessica Mega
Presenter: Jessica Mega | see Discussant report
BackgroundPatients remain at risk of recurrent cardiovascular events despite medical therapies and interventional strategies following a ST-segment elevation myocardial infarction (STEMI). In the ATLAS ACS 2-TIMI 51 trial, the factor Xa inhibitor rivaroxaban reduced cardiovascular events in ACS patients. The present analysis reports the results of rivaroxaban versus placebo in the pre-specified subgroup of patients following a STEMI.
MethodsATLAS ACS 2-TIMI 51 was a randomized, placebo-controlled study involving 44 countries and 15,526 patients. The present analysis includes 7,817 patients following a STEMI who underwent randomization to twice daily dosing of either rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo. Data are presented as 2 year Kaplan–Meier event rates, and testing was based on the log-rank test, stratified by the intention to use a thienopyridine.
ResultsRivaroxaban was associated with a reduction in the composite primary efficacy endpoint of cardiovascular death, myocardial infarction, or stroke, as compared with placebo (8.4% vs. 10.6%, HR 0.81, 95% CI 0.67-0.97, P=0.019). Rivaroxaban 2.5 mg twice daily (8.7% vs. 10.6%, P=0.047) and 5 mg twice daily (8.2% vs. 10.6%, P=0.051) as compared with placebo exhibited directionally consistent reductions in the primary efficacy endpoint. Rivaroxaban 2.5 mg twice daily reduced cardiovascular death (2.5% vs. 4.2%, P=0.006) and all-cause death (3.0% vs. 4.7%, P=0.008); this survival benefit was not seen with 5 mg twice daily dose. Rivaroxaban, as compared with placebo, increased the rates of TIMI major bleeding not related to CABG (2.2% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.1%, P=0.015), without a significant increase in fatal bleeding (0.2% vs. 0.1%, P=0.51). Rivaroxaban 2.5 mg twice daily resulted in less fatal bleeding than rivaroxaban 5 mg twice daily (1 event vs. 8 events, P=0.018).
SummaryIn patients with a recent STEMI, rivaroxaban reduced the risk of the composite endpoint of cardiovascular death, myocardial infarction, or stroke, and the 2.5 mg twice daily dose demonstrated a mortality benefit. Rivaroxaban as compared with placebo increased the risk of major bleeding and intracranial hemorrhage, but there was no increase in fatal bleeding.
ConclusionsTreatment with very low dose rivaroxaban (2.5 mg BID) offers an effective strategy to reduce thrombotic events in patients following a STEMI.
Discussant: Andreas Michael | see Presenter abstract
710007 - 710008
Clinical Trial & Registry Update II: Updates on Heart Failure and Coronary Artery Disease
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved